# US 2017/0000881 A1 · Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0000881 A1
- Document ID: US20170000881A1
- Status: Published application
- Kind: A1
- Application number: 15/211,362
- Filed: 2016-07-15
- Published: 2017-01-05
- Earliest claimed: 2007-09-14
- Assignees: Vrije Universiteit Brussel
- Applicants: Vrije Universiteit Brussel
- Inventors: Kris Maria Magdalena Thielemans; Aude Bonehill
- Web page: https://patentgrep.com/patent/US20170000881A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/4245: {Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]}
- A61K 40/4268: {MAGE}
- A61K 40/4272: {Melan-A/MART}
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- A61K 40/50: characterised by the use of allogeneic cells
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- A61K 2239/57: Skin; melanoma
- C12N 2510/00: Genetically modified cells
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

We provide new methods of in vitro or in vivo enhancing the T-cell stimulatory capacity of human DCs and the use thereof in cancer vaccination. The method includes the introduction of different molecular adjuvants to human DCs by contacting or modifying them with mRNA or DNA molecule(s) encoding CD40L, and CD70 or constitutively active TLR4 (caTLR4).

## Claims

### Claim 1

A method for the treatment of infectious diseases, said method comprising administering to a subject in need thereof one or more isolated mRNA molecule(s) encoding for:
a functional immunostimulatory protein CD40L, constitutively active TLR4 (caTLR4), and a functional immunostimulatory protein CD70; wherein said method does not include the administration of dendritic cells to said subject.

### Claim 2 (depends on 1)

The method according to claim 1, additionally comprising administering target-specific antigen(s) before, after, or simultaneously with the one or more isolated mRNA molecule(s).

### Claim 3 (depends on 2)

The method of claim 2, wherein the target-specific antigen(s) is selected from a bacterial antigen, a viral antigen, or a fungal antigen.

### Claim 4 (depends on 2)

The method of claim 2, wherein said target-specific antigen(s) is selected from the group consisting of: total mRNA isolated from (a) target cell(s), one or more specific target mRNA molecules, protein lysates of (a) target cell(s), specific proteins from (a) target cell(s), a synthetic target-specific peptide or protein, and synthetic mRNA or DNA encoding a target-specific antigen or its derived peptide(s).

### Claim 5 (depends on 1)

The method of claim 1, additionally comprising the administration of mRNA or DNA encoding one or more of the following molecules: IL-12p70, EL-selectin, CCR7, or 4-1BBL.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said one or more isolated mRNA molecule(s) encoding the immunostimulatory proteins are part of a single mRNA molecule.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the single mRNA molecule is capable of expressing the two or more proteins simultaneously.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said one or more isolated mRNA molecule(s) is protected.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the infectious disease is selected from:
virus-caused infections selected from: Acquired Immunodeficiency Syndrome, Adenoviridae Infections, Alphavirus Infections, Arbovirus Infections, Bell Palsy, Boma Disease, Bunyaviridae Infections, Caliciviridae Infections, Chickenpox, Common Cold, Condyloma Acuminata, Coronaviridae Infections, Coxsackievirus Infections, Cytomegalovirus Infections, Dengue, DNA Virus Infections, Contagious Ecthyma, Encephalitis, Arbovirus-Encephalitis, Herpes Simplex, Epstein-Barr Virus Infections, Erythema Infectiosum, Exanthema Subitum, Fatigue Syndrome, Chronic Hantavirus Infections, Hemorrhagic Fevers, Viral Hepatitis, Viral Human Herpes, Labia Herpes, Simplex Herpes, Zoster Herpes, Zoster Oticus Herpesviridae Infections, HIV Infections, Infectious Mononucleosis, Influenza in Birds, Influenza, Human Lassa Fever, Measles, Meningitis, Viral Molluscum Contagiosum, Monkeypox, Mumps, Myelitis, Papillomavirus infections, Paramyxoviridae Infections, Phlebotomus Fever, Poliomyelitis, Polyomavirus Infections, Postpoliomyelitis Syndrome, Rabies, Respiratory Syncytial Virus infections, Rift Valley Fever, RNA Virus Infections, Rubella, Severe Acute Respiratory Syndrome, Slow Virus Diseases, Smallpox, Subacute Sclerosing Panencephalitis, Tick-Borne Diseases, Tumor Virus Infections, Warts, West Nile Fever, Yellow Fever, or Zoonoses; or
bacteria- or fungus-caused infections selected from: Abscess, Actinomycosis, Anaplasmosis, Anthrax, Arthritis, Reactive Aspergillosis, Bacteremia, Bacterial Infections, Mycoses, Bartonella Infections, Botulism, Brain Abscess, Brucellosis, Burkholderia Infections, Campylobacter Infections, Candidiasis Vulvovaginal, Cat-Scratch Disease, Cellulitis, Central Nervous System Infections, Chancroid, Chlamydia Infections, Chlamydiaceae Infections, Cholera, Clostridium Infections, Coccidioidomycosis, Corneal Ulcer-Cross Infection, Cryptococcosis, Dermatomycoses, Diphtheria, Ehrlichiosis, Empyema, Pleural Endocarditis, Bacterial Endophthalmitis, Enterocolitis, Pseudomembranous Erysipelas, Escherichia coli Infections, Fasciitis, Necrotizing Fournier Gangrene, Furunculosis, Fusobacterium Infections, Gas Gangrene, Gonorrhea, Gram-Negative Bacterial Infections, Gram-Positive Bacterial Infections, Granuloma Inguinale, Hidradenitis Suppurativa, Histoplasmosis, Hordeolum, Impetigo, Klebsiella Infections, Legionellosis, Leprosy, Leptospirosis, Listeria Infections, Ludwig's Angina, Lung Abscess, Lyme Disease, Lymphogranuloma Venereum, Maduromycosis, Melioidosis, Meningitis Bacterial, Mycobacterium Infections, Mycoplasma infections, Mycoses, Nocardia Infections, Onychomycosis, Osteomyelitis, Paronychia, Inflammatory Disease, Plague, Pneumococcal Infections, Pseudomonas Infections, Psittacosis, Puerperal Infection, Q Fever, Rat-Bite Fever, Relapsing Fever, Respiratory Tract Infections, Retropharyngeal Abscess, Rheumatic Fever, Rhinoscleroma, Rickettsia Infections, Rocky Mountain Spotted Fever, Salmonella Infections, Scarlet Fever, Scrub Typhus, Sepsis, Sexually Transmitted Diseases, Bacterial Sexually Transmitted Diseases, Bacterial Shock, Septic Skin Diseases, Bacterial Skin Diseases, infectious Staphylococcal Infections, Streptococcal Infections, Syphilis, Syphilis Congenital, Tetanus, Tick-Borne Diseases, Tinea, Tinea Versicolor, Trachoma, Tuberculosis, Spinal Tularemia, Typhoid Fever, Typhus Epidemic Louse Borne, Urinary Tract Infections, Whipple Disease, Whooping Cough, Vibrio Infections, Yaws, Yersinia Infections, Zoonoses, or Zygomycosis.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the method does not include the administration of a target specific antigen to said subject.
